Immunovant, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended September 30, 2022, Immunovant’s fiscal second quarter of fiscal 2023. The financial statements are unaudited and prepared under U.S. GAAP. Immunovant is a clinical-stage biopharmaceutical company developing the FcRn-targeting antibodies batoclimab and IMVT-1402 for autoimmune diseases.
Financial performance and liquidity
| Metric | Three months ended September 30 | Six months ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $37.7 million | $66.2 million |
| General and administrative expense | $11.9 million | $23.8 million |
| Total operating expenses | $49.6 million | $90.0 million |
| Net loss | $47.9 million | $88.3 million |
| Basic and diluted loss per share | $0.41 | $0.76 |
| Net cash used in operating activities | Not separately presented | $86.0 million |
- Research and development expense increased 77% for the quarter and 65% for the six-month period versus the prior comparable periods, primarily because of resumed and expanded clinical activity, including the Phase 3 myasthenia gravis program, planned CIDP activity, manufacturing, and IMVT-1402 development.
- General and administrative expense decreased 27% for the quarter and 13% for the six-month period, mainly due to lower financial advisory, legal and other professional fees, partly offset by higher personnel and information technology costs.
- Net loss increased from $37.7 million to $47.9 million for the quarter and from $68.2 million to $88.3 million for the six-month period. Interest income contributed $1.2 million during the six months ended September 30, 2022.
- Gross and operating margins are not meaningful because the company has no product revenue. The company has never generated product revenue and expects continued losses.
- Cash and cash equivalents were $405.8 million at September 30, 2022, down from $493.8 million at March 31, 2022. Current assets were $426.1 million and total liabilities were $32.4 million.
- The filing does not disclose outstanding funded debt; liabilities primarily comprise accounts payable, accrued expenses, and operating lease liabilities.
- Stock-based compensation was $15.6 million for the six-month period, including $7.4 million in research and development and $8.2 million in general and administrative expense.
Material changes versus the prior comparable period
- Clinical development spending accelerated as the company initiated its Phase 3 batoclimab trial in myasthenia gravis in June 2022 and prepared additional trials in thyroid eye disease, CIDP, Graves’ disease, and IMVT-1402.
- Batoclimab program-specific research and development expense increased to $15.3 million for the quarter and $25.4 million for the six months, while IMVT-1402 expense was $4.3 million and $4.7 million, respectively; no comparable IMVT-1402 expense was reported in the prior-year periods.
- Operating cash use more than doubled for the six months, from $41.3 million to $86.0 million, reflecting higher losses, clinical activity, manufacturing costs, and prepaid clinical research expenditures.
- Financing cash inflows were minimal during the six months ended September 30, 2022, compared with $200.0 million received from Roivant Sciences Ltd. in the prior-year period.
- Common shares outstanding increased to 116.6 million at September 30, 2022 from 116.5 million at March 31, 2022. As of October 28, 2022, 129.2 million shares were outstanding.
Guidance, outlook, risks, and unusual items
- Management expected the September 30 cash balance to fund operating expenses and capital expenditures for at least the next 12 months. Including approximately $70.2 million of net proceeds from an October 2022 underwritten offering, management expected funding into the second half of calendar year 2025, subject to assumptions that may prove incorrect.
- In October 2022, the company issued 12.5 million common shares, including 416,667 shares purchased by Roivant, at $6.00 per share for approximately $70.2 million of net proceeds.
- Management expects research and development expense and operating losses to increase as additional clinical trials, manufacturing activities, regulatory work, and staffing requirements expand. The company states that current funds will not be sufficient to complete all development and commercial-launch activities.
- Planned milestones include batoclimab Phase 3 myasthenia gravis top-line data in the second half of calendar 2024, thyroid eye disease Phase 3 results in the first half of calendar 2025, CIDP initial data in the first half of calendar 2024, Graves’ disease initial data in the second half of calendar 2023, and IMVT-1402 Phase 1 initial data in mid-calendar 2023, contingent on IND clearance.
- The Samsung manufacturing agreement carries an estimated minimum purchase commitment of approximately $36.0 million, with $17.7 million expected in fiscal 2023 and $18.3 million in fiscal 2026. Approximately $1.7 million was accrued at September 30, 2022.
- The HanAll license agreement includes potential future milestone payments of up to $442.5 million, reimbursement of up to $20.0 million of specified research and development costs, and tiered royalties ranging from the mid-single digits to mid-teens percentage of net sales.
- Batoclimab development remains exposed to previously observed treatment-related increases in total cholesterol and LDL levels and reductions in albumin. The company had voluntarily paused earlier batoclimab dosing in 2021 while evaluating these findings.
- The company has no approved products, has not submitted a BLA for either candidate, relies on contract research organizations and manufacturers, and faces clinical, regulatory, manufacturing, intellectual property, competitive, reimbursement, and financing risks.
- A putative securities class action regarding alleged misleading statements about batoclimab safety remained pending. The company had not accrued a liability because the possible loss could not be reasonably estimated and an unfavorable outcome was not determined to be probable.
- Roivant Sciences Ltd. beneficially owned approximately 57.1% of voting power as of October 28, 2022, resulting in controlled-company status and significant influence over corporate matters.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2022, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress, enrollment, safety findings, and timing of data readouts for the batoclimab and IMVT-1402 clinical programs.
- Whether lipid and albumin effects remain manageable in longer-duration or higher-dose batoclimab studies.
- Actual cash-burn trends and whether the stated funding runway through the second half of calendar 2025 remains valid.
- Potential dilution from the October 2022 offering, equity awards, and any future capital raises.
- Future HanAll milestone obligations, royalties, and Samsung manufacturing commitments.
- Developments and potential exposure from the securities class action and other legal proceedings.
- Regulatory feedback, IND clearance for IMVT-1402, and any future BLA submission plans.